CEPHALOSPORIN DRUGS MARKET ANALYSIS

Cephalosporin Drugs Market, By Generation (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2019 - 2026

Published In : Jul 2019
Code : CMI2893
Pages :236
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Cephalosporin Drugs Market - Restraints

Increasing cephalosporin drug recalls by regulatory bodies is hampering the cephalosporin drugs market growth. For instance, in August 2014, Caraco Pharmaceutical Laboratories Ltd., a unit of Sun Pharmaceutical Industries Ltd., initiated a recall of multiple lots of Cephalexin capsules from the U.S. market. According to a notification by the U.S. FDA, the recall of 340,553 units of 500 mg and 113,677 units of 250 mg bottles was voluntarily initiated by the company through a letter to the regulator in June 2014 under ‘Class-II’ classification, owing to Current Good Manufacturing Practice (CGMP) deviations.